Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Sims

Showing results (691-700 of 711) with videos related to

Pageof 72
Sort By:
Bioorganic & Medicinal Chemistry Letters|April 9, 2015
Development of methyl isoxazoleazepines as inhibitors of BETMichael C Hewitt, Yves Leblanc, Victor S Gehling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor MicroenvironmentYinshi Huang, Sabikun Nahar, Akifumi Nakagawa, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET BromodomainsAlexander M Taylor, Rishi G Vaswani, Victor S Gehling, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery, Design, and Optimization of Isoxazole Azepine BET InhibitorsVictor S Gehling, Michael C Hewitt, Rishi G Vaswani, et al.
JAMA Internal Medicine|January 31, 2017
Implementation of Lung Cancer Screening in the Veterans Health AdministrationLinda S Kinsinger, Charles Anderson, Jane Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)Keith T Flaherty, Robert J Gray, Alice P Chen, et al.
Journal of Medicinal Chemistry|January 28, 2016
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical TrialsBrian K Albrecht, Victor S Gehling, Michael C Hewitt, et al.
Nature Medicine|June 15, 2023
The NCI-MATCH trial: lessons for precision oncologyPeter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Plos One|November 13, 2009
Visualization and identification of IL-7 producing cells in reporter miceRenata I Mazzucchelli, Søren Warming, Scott M Lawrence, et al.
Journal of Medicinal Chemistry|August 5, 2022
GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1Alexander M Taylor, Chris Bailey, Lisa D Belmont, et al.
Pageof 72

Showing results (691-700 of 711) with videos related to

Sort By:
Pageof 72
Bioorganic & Medicinal Chemistry Letters|April 9, 2015
Development of methyl isoxazoleazepines as inhibitors of BETMichael C Hewitt, Yves Leblanc, Victor S Gehling, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2016
Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor MicroenvironmentYinshi Huang, Sabikun Nahar, Akifumi Nakagawa, et al.
ACS Medicinal Chemistry Letters|March 18, 2016
Discovery of Benzotriazolo[4,3-d][1,4]diazepines as Orally Active Inhibitors of BET BromodomainsAlexander M Taylor, Rishi G Vaswani, Victor S Gehling, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery, Design, and Optimization of Isoxazole Azepine BET InhibitorsVictor S Gehling, Michael C Hewitt, Rishi G Vaswani, et al.
JAMA Internal Medicine|January 31, 2017
Implementation of Lung Cancer Screening in the Veterans Health AdministrationLinda S Kinsinger, Charles Anderson, Jane Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 13, 2020
Molecular Landscape and Actionable Alterations in a Genomically Guided Cancer Clinical Trial: National Cancer Institute Molecular Analysis for Therapy Choice (NCI-MATCH)Keith T Flaherty, Robert J Gray, Alice P Chen, et al.
Journal of Medicinal Chemistry|January 28, 2016
Identification of a Benzoisoxazoloazepine Inhibitor (CPI-0610) of the Bromodomain and Extra-Terminal (BET) Family as a Candidate for Human Clinical TrialsBrian K Albrecht, Victor S Gehling, Michael C Hewitt, et al.
Nature Medicine|June 15, 2023
The NCI-MATCH trial: lessons for precision oncologyPeter J O'Dwyer, Robert J Gray, Keith T Flaherty, et al.
Plos One|November 13, 2009
Visualization and identification of IL-7 producing cells in reporter miceRenata I Mazzucchelli, Søren Warming, Scott M Lawrence, et al.
Journal of Medicinal Chemistry|August 5, 2022
GNE-064: A Potent, Selective, and Orally Bioavailable Chemical Probe for the Bromodomains of SMARCA2 and SMARCA4 and the Fifth Bromodomain of PBRM1Alexander M Taylor, Chris Bailey, Lisa D Belmont, et al.
Pageof 72